Safety of Intravenous Methamphetamine Administration During Ibudilast Treatment.

ABSTRACT:

Background

Methamphetamine dependence is a significant public health concern without any approved medications for treatment. We evaluated ibudilast, a nonselective phosphodiesterase inhibitor, to assess the safety and tolerability during intravenous methamphetamine administration. We conducted a randomized, double-blind, placebo-controlled, within-subjects crossover clinical trial.

Methods

Participants received ibudilast (20 mg twice daily followed by 50 mg twice daily) and placebo, with order determined by randomization, and then underwent intravenous methamphetamine challenges (15 and 30 mg). We monitored cardiovascular effects, methamphetamine pharmacokinetics, and reported adverse events.

Results

Ibudilast treatment had similar rates of adverse events compared wit

SUBMITTER: DeYoung DZ 

PROVIDER: S-EPMC4927401 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature